<DOC>
	<DOCNO>NCT00776516</DOCNO>
	<brief_summary>The objective study ass PK , safety tolerability single dose mirabegron alone combination repeat dose rifampin , potent CYP3A4 inducer .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Study Assess Effect Repeat Doses Rifampin Mirabegron ( YM178 ) Healthy Volunteers</brief_title>
	<detailed_description>A single group patient receive mirabegron alone combination rifampin</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Weighs least 45 kg body mass index ( BMI ) 18 32 kg/m2 Screening Normal clinically significant 12 lead ECG clinical laboratory test result Screening Female subject must postmenopausal , surgically sterile since least 1 month prior screening , practice effective nonhormonal contraceptive method . All female must nonlactating , negative result pregnancy test Screening Day 1 Negative drug alcohol screen Has know suspect hypersensitivity mirabegron rifampin Liver enzyme test abnormality ( ALT , AST , bilirubin ) upper limit normal History presence psychiatric illness , serious active recurrent infection hepatitis Previous history cancer basal cell carcinoma Stage 1 squamous cell carcinoma remission least 5 year prior dose study drug Donation loss â‰¥ 450 mL blood within 56 day prior study drug administration donate plasma within 7 day prior study drug administration Received anticipate receive prescription drug within 14 day prior Day 1 within 30 day prior Day 1 long acting treatment . Use overthecounter medication , include complementary alternative medicine ( except occasional use acetaminophen 2000 mg/day 4 day per week ) within 14 day prior Day 1 History substance abuse within 6 month prior Screening Current participation another clinical trial take take investigational drug 30 day 10 half life drug , whichever longer , prior dose Known hepatitis HIV1 and/or HIV2 positive hepatitis A antibody IgM , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody Screening Subject consume alcohol , caffeinecontaining food beverage , grapefruit juice , grapefruitcontaining product Seville orange within 48 prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Healthy volunteer subject</keyword>
	<keyword>CYP3A4 inducer</keyword>
	<keyword>rifampin</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>YM178</keyword>
	<keyword>mirabegron</keyword>
</DOC>